Array Pharmaceuticals and NSLC

Non small lung cancer (NSLC) is a devastating disease, and usually by the time it is diagnosed its almost too late to treat. My mom died of NSLC. She went very quickly , and the cancer cells took over her body. If we could find an effective treatment for this terrible disease, many people would not suffer as my mom did.

Array BioPharma (ARRY) provided some new data on treatment of KRAS Mutant advanced NSCLC patients. Many people in the US with NSCLC have the KRAS mutant In a double blind, randomized phase 2 study conducted by AstraZeneca examined the efficacy of selumetinib (AZD6244/ARRY886) with docetaxel in patients with the KRAS mutant had progressive free at least 6 months and improved overall survival.

From http://www.datamonitor.com/ compliments of scottrade. So what about the stock? It is not doing any remarkable climbing, but it is increasing slowly. I would recommend this as a long term investment. Just my 2 cents!

Please check out : http://amazingwonders-of-kindle.blogspot.com/ too!